GO:0032347 regulation of aldosterone biosynthetic process: Biosynthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032347 describes any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of aldosterone.
• Aldosterone biosynthesis is primarily regulated by the renin-angiotensin-aldosterone system (RAAS), which is modulated by cyclic nucleotides and phosphodiesterases.
• Somatic mutations, such as those in CADM1, are found in aldosterone-producing adenomas and can drive gap junction-dependent regulation of aldosterone production.
• Primary aldosteronism is a common cause of secondary hypertension, and dysregulation of aldosterone biosynthesis contributes to its pathogenesis.
• Beyond blood pressure, aldosterone exerts non-hypertensive effects including inflammation, fibrosis, and cardiovascular remodeling.
• Key genes involved include CYP11B2, AGT, REN, ACE, AGTR1, and CADM1, among others.
Description
The regulation of aldosterone biosynthetic process (GO:0032347) encompasses any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of aldosterone. Aldosterone is a mineralocorticoid hormone produced in the adrenal cortex, and its biosynthesis is tightly controlled to maintain electrolyte balance and blood pressure. Dysregulation of this process is implicated in primary aldosteronism, a major cause of secondary hypertension. Understanding the regulatory mechanisms is crucial for developing targeted therapies and for interpreting genetic and pharmacological studies. This article integrates authoritative GO data and verified literature to provide a comprehensive overview of the term, its associated genes, and research methodologies.
regulation of aldosterone biosynthetic process At A Glance
| GO ID | GO:0032347 |
|---|---|
| GO term | regulation of aldosterone biosynthetic process |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulation of aldosterone production |
| Definition | Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of aldosterone. |
| Related diseases | Primary aldosteronism, hypertension, cardiovascular fibrosis |
| Key regulators | RAAS components, cyclic nucleotides, phosphodiesterases, CADM1 |
What Is GO:0032347?
GO:0032347 is a biological process term defined as any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of aldosterone. In other words, it covers all regulatory inputs—hormonal, genetic, or pharmacological—that influence how much aldosterone is produced by the adrenal glands.
Why Is regulation of aldosterone biosynthetic process Important in Cell Biology?
The regulation of aldosterone biosynthesis is critical for cardiovascular and renal physiology, as aldosterone controls sodium retention, potassium excretion, and blood pressure. Dysregulation leads to primary aldosteronism, a common cause of secondary hypertension, and contributes to adverse cardiovascular and renal outcomes. Moreover, aldosterone has non-hypertensive effects, including promotion of inflammation and fibrosis, making its regulation a therapeutic target. Research into this process aids in understanding adrenal pathophysiology and in developing new treatments for hypertension and related disorders.
• Maintains electrolyte and fluid balance through regulation of aldosterone synthesis.
• Dysregulation causes primary aldosteronism, a leading cause of secondary hypertension.
• Aldosterone excess contributes to cardiovascular fibrosis and inflammation.
• Non-hypertensive effects of aldosterone affect multiple organ systems.
• Genetic mutations in aldosterone-producing adenomas alter regulation.
• Cyclic nucleotide signaling modulates RAAS and aldosterone production.
• Ion channels influence aldosterone secretion and regulation.
• Substance P and neurokinin receptors regulate aldosterone in adenomas.
• Novel genetic determinants continue to be discovered.
• Targeting aldosterone regulation offers therapeutic potential for hypertension.
What Happens During regulation of aldosterone biosynthetic process?
Initiation by RAAS Activation
In simple terms: The process starts when the renin-angiotensin system is turned on.
The renin-angiotensin-aldosterone system (RAAS) is a primary regulator of aldosterone biosynthesis. Reduced renal perfusion triggers renin release, leading to angiotensin II production, which stimulates aldosterone synthesis in the adrenal cortex. This cascade is modulated by cyclic nucleotides and phosphodiesterases, which fine-tune the response.
Transcriptional Control of CYP11B2
In simple terms: The gene for the final enzyme in aldosterone production is switched on.
Angiotensin II and potassium elevate intracellular calcium, activating transcription factors that increase expression of CYP11B2 (aldosterone synthase), the rate-limiting enzyme for aldosterone biosynthesis. Mutations in genes such as CADM1 can alter this transcriptional regulation in adenomas.
Post-Transcriptional and Post-Translational Modulation
In simple terms: The enzyme's activity and stability are adjusted after it is made.
Cyclic AMP and cyclic GMP signaling pathways, regulated by phosphodiesterases, influence the stability and activity of aldosterone synthase and upstream regulators. Ion channels, such as potassium channels, modulate membrane potential and calcium influx, affecting enzyme activity.
Feedback and Fine-Tuning
In simple terms: The system has brakes to prevent overproduction.
Aldosterone itself feeds back to inhibit renin release, while sodium and potassium levels modulate the sensitivity of the adrenal cortex. Disruption of this feedback, as seen in primary aldosteronism, leads to autonomous aldosterone production.
Role of Gap Junctions and Cell-Cell Communication
In simple terms: Cells talk to each other to coordinate aldosterone output.
Gap junction proteins, such as CADM1, mediate cell-cell communication in the adrenal cortex and regulate aldosterone production. Somatic mutations in CADM1 disrupt this communication and are associated with aldosterone-producing adenomas.
Key Genes Involved in GO:0032347 regulation of aldosterone biosynthetic process
The following genes are key players in the regulation of aldosterone biosynthetic process, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP11B2 | Aldosterone synthase; catalyzes final steps of aldosterone synthesis | Rate-limiting enzyme; target for mutations and expression studies |
| REN | Renin; initiates RAAS cascade | Regulates aldosterone production; biomarker for RAAS activity |
| AGT | Angiotensinogen; precursor of angiotensin peptides | Genetic variants affect aldosterone regulation |
| ACE | Angiotensin-converting enzyme; generates angiotensin II | Modulates RAAS and aldosterone synthesis |
| AGTR1 | Angiotensin II receptor type 1; mediates aldosterone stimulation | Target for pharmacological inhibition |
| CADM1 | Cell adhesion molecule; gap junction-dependent regulation | Somatic mutations in aldosterone-producing adenomas |
| KCNJ5 | Potassium channel; regulates membrane potential and calcium signaling | Mutations cause aldosterone excess |
| ATP1A1 | Sodium/potassium ATPase; affects ion balance | Mutations linked to aldosteronism |
| CACNA1D | Calcium channel; controls calcium influx | Mutations increase aldosterone production |
| TACR1 | Neurokinin 1 receptor; mediates substance P effects | Regulates aldosterone in adenomas |
| PDE2A | Phosphodiesterase; modulates cyclic nucleotide levels | Regulates RAAS and aldosterone |
| PDE3A | Phosphodiesterase; modulates cyclic nucleotide levels | Regulates RAAS and aldosterone |
| PRKACA | Protein kinase A; downstream of cAMP | Modulates aldosterone synthesis |
| PRKACG | Protein kinase G; downstream of cGMP | Modulates aldosterone synthesis |
| NR4A1 | Nuclear receptor; transcription factor | Regulates CYP11B2 expression |
| NR4A2 | Nuclear receptor; transcription factor | Regulates CYP11B2 expression |
| ATF2 | Transcription factor; mediates stress responses | Involved in aldosterone regulation |
| NR5A1 | Steroidogenic factor 1; master regulator of steroidogenesis | Controls adrenal development and aldosterone synthesis |
How Is regulation of aldosterone biosynthetic process Regulated?
The regulation of aldosterone biosynthetic process is itself subject to multiple layers of control. The RAAS is the primary regulator, but cyclic nucleotides (cAMP and cGMP) and phosphodiesterases modulate the signaling cascade. Ion channels, including potassium and calcium channels, influence membrane potential and calcium influx, which are critical for CYP11B2 expression and activity. Additionally, cell-cell communication via gap junctions, involving proteins like CADM1, fine-tunes aldosterone production in the adrenal cortex. Neuroendocrine factors such as substance P and its receptor TACR1 also regulate aldosterone secretion in adenomas. These regulatory mechanisms ensure appropriate aldosterone levels and are disrupted in pathological states such as primary aldosteronism.
regulation of aldosterone biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP11B2 | Primary aldosteronism | Knockout or point mutation in adrenal cell lines |
| CADM1 | Aldosterone-producing adenomas | Knock-in of somatic mutations in HAC15 cells |
| KCNJ5 | Primary aldosteronism | Overexpression of mutant channels in adrenocortical cells |
| AGTR1 | Hypertension | Knockout in mouse models |
| TACR1 | Aldosterone regulation in adenomas | Knockdown or knockout in primary adrenal cells |
Primary Aldosteronism and Hypertension
Primary aldosteronism, characterized by autonomous aldosterone overproduction, is a common cause of secondary hypertension. Dysregulation of aldosterone biosynthesis, often due to genetic mutations or adrenal adenomas, leads to excessive aldosterone and subsequent hypertension, hypokalemia, and cardiovascular damage. Somatic mutations in genes such as CADM1 and KCNJ5 are implicated in aldosterone-producing adenomas.
Cardiovascular and Renal Fibrosis
Aldosterone excess beyond blood pressure effects promotes inflammation, fibrosis, and remodeling in the heart and kidneys. This is mediated through mineralocorticoid receptor activation and is independent of hypertension. Understanding the regulation of aldosterone biosynthesis is crucial for developing therapies to mitigate these adverse effects.
Metabolic and Other Non-Hypertensive Effects
Aldosterone has been linked to metabolic syndrome, insulin resistance, and vascular dysfunction. These non-hypertensive effects expand the clinical importance of aldosterone regulation beyond blood pressure control. Research into the regulatory mechanisms may reveal new therapeutic targets.
From regulation of aldosterone biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate aldosterone production? | Knockout of gene X in HAC15 or primary adrenal cells |
| Does mutation Y affect aldosterone synthase activity? | Point mutation knock-in in CYP11B2 |
| Does overexpression of gene Z increase aldosterone? | Overexpression of gene Z in adrenocortical cells |
| Does tagging of protein affect localization? | Tagged knock-in of gene of interest |
| Does gene X affect RAAS signaling? | Knockout in mouse models with RAAS monitoring |
| Does mutation in CADM1 alter gap junction function? | Knock-in of CADM1 mutation in adrenal cells |
How to Study the regulation of aldosterone biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression levels | Identify differentially expressed genes in aldosterone-producing adenomas |
| Proteomics | Protein abundance and modifications | Quantify aldosterone synthase and regulatory proteins |
| ELISA | Aldosterone concentration | Measure hormone secretion in cell culture |
| Patch-clamp | Ion channel activity | Assess potassium and calcium channel function |
| Calcium imaging | Intracellular calcium levels | Monitor signaling in response to stimuli |
| CRISPR knockout | Gene function loss | Validate candidate regulators of aldosterone synthesis |
| CRISPR knock-in | Specific mutations | Model somatic mutations found in adenomas |
| ChIP-seq | Transcription factor binding | Map regulatory regions of CYP11B2 |
Transcriptomic Analysis
RNA sequencing (RNA-seq) can quantify expression of genes involved in aldosterone biosynthesis, such as CYP11B2, and identify regulatory networks. This method is useful for comparing adrenal tissues from patients with primary aldosteronism versus controls.
Proteomic and Metabolomic Profiling
Mass spectrometry-based proteomics and metabolomics can measure aldosterone synthase protein levels and steroid metabolites, providing insights into flux through the biosynthetic pathway.
Functional Assays
Aldosterone secretion can be measured by ELISA or radioimmunoassay in cell culture media. Calcium imaging and patch-clamp electrophysiology assess ion channel activity and membrane potential.
Genetic and Epigenetic Editing
CRISPR-Cas9 gene editing enables knockout, knock-in, or point mutations to study gene function. This approach is valuable for validating candidate genes identified from genomic studies.
How CRISPR Can Be Used to Study GO:0032347 regulation of aldosterone biosynthetic process
Knockout
CRISPR knockout of candidate genes such as CYP11B2 or CADM1 in adrenal cell lines can determine their necessity for aldosterone biosynthesis. This approach helps validate genetic findings from patient samples.
Point Mutation
Introducing specific point mutations (e.g., in KCNJ5 or ATP1A1) using CRISPR base editing or HDR can model somatic mutations found in aldosterone-producing adenomas and assess their impact on aldosterone regulation.
Knock-in
Knock-in of reporter genes or tags (e.g., GFP) into the CYP11B2 locus allows real-time monitoring of aldosterone synthase expression and localization in live cells.
Overexpression
Overexpression of wild-type or mutant genes (e.g., CADM1, TACR1) via lentiviral vectors can mimic gain-of-function states and elucidate their role in aldosterone overproduction.
How EDITGENE Supports regulation of aldosterone biosynthetic process Research
Researchers studying regulation of aldosterone biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in aldosterone production or merely correlated. EDITGENE provides specialized CRISPR services to enable precise genetic manipulation in adrenal cell models, accelerating functional validation.
Contact EDITGENE today to design your custom CRISPR model for regulation of aldosterone biosynthetic process research.
Frequently Asked Questions About regulation of aldosterone biosynthetic process
What is GO:0032347?
GO:0032347 is the Gene Ontology term for regulation of aldosterone biosynthetic process, defined as any process that modulates the frequency, rate or extent of aldosterone formation.
What genes are involved in regulation of aldosterone biosynthetic process?
Key genes include CYP11B2, REN, AGT, ACE, AGTR1, CADM1, KCNJ5, ATP1A1, CACNA1D, and TACR1, among others.
How is aldosterone biosynthesis regulated?
It is primarily regulated by the renin-angiotensin-aldosterone system, with modulation by cyclic nucleotides, phosphodiesterases, ion channels, and cell-cell communication.
What diseases are associated with dysregulation of aldosterone biosynthesis?
Primary aldosteronism, hypertension, cardiovascular fibrosis, and metabolic syndrome are associated with dysregulated aldosterone biosynthesis.
What is the role of CADM1 in aldosterone regulation?
CADM1 mediates gap junction-dependent regulation of aldosterone production, and somatic mutations in CADM1 are found in aldosterone-producing adenomas.
How do cyclic nucleotides affect aldosterone biosynthesis?
Cyclic AMP and cyclic GMP, regulated by phosphodiesterases, modulate the RAAS and downstream signaling to influence aldosterone synthesis.
What experimental models are used to study aldosterone regulation?
Common models include adrenal cell lines (e.g., HAC15), primary adrenal cells, and mouse models with genetic modifications.
What is primary aldosteronism?
Primary aldosteronism is a condition of autonomous aldosterone overproduction, often caused by adrenal adenomas or hyperplasia, leading to hypertension and hypokalemia.
How can CRISPR be used to study aldosterone biosynthesis?
CRISPR can create knockout, knock-in, or point mutations in genes like CYP11B2 or CADM1 to assess their function in aldosterone production.
What are the non-hypertensive effects of aldosterone?
Aldosterone promotes inflammation, fibrosis, and remodeling in the heart, kidneys, and vasculature, independent of blood pressure.
Conclusion
The regulation of aldosterone biosynthetic process (GO:0032347) is a critical biological process with profound implications for cardiovascular and renal health. Dysregulation leads to primary aldosteronism and contributes to hypertension and organ damage. Ongoing research into the genetic and signaling mechanisms, facilitated by CRISPR-based models, promises to uncover new therapeutic targets. EDITGENE's specialized services support these efforts by providing precise genetic tools for functional studies.
References
- 1. Wu X et al.. 2023. Somatic mutations of CADM1 in aldosterone-producing adenomas and gap junction-dependent regulation of aldosterone production.. Nat Genet 55(6):1009-1021 PMID: 37291193
- 2. Gambaryan S et al.. 2023. Regulation of the renin-angiotensin-aldosterone system by cyclic nucleotides and phosphodiesterases.. Front Endocrinol (Lausanne) 14:1239492 PMID: 37674612
- 3. Gordon RD. 1995. Primary aldosteronism.. J Endocrinol Invest 18(7):495-511 PMID: 9221268
- 4. Lopez AG et al.. 2026. Regulation of Aldosterone Secretion by Substance P and the Neurokinin Type 1 Receptor in Aldosterone-Producing Adenomas.. J Am Heart Assoc 15(2):e045539 PMID: 41532541
- 5. Ekman N et al.. 2025. Non-Hypertensive Effects of Aldosterone.. Int J Mol Sci 26(2) PMID: 39859256
- 6. Azizan EA et al.. 2016. Novel genetic determinants of adrenal aldosterone regulation.. Curr Opin Endocrinol Diabetes Obes 23(3):209-17 PMID: 26992195
- 7. Brown JM. 2024. Adverse Effects of Aldosterone: Beyond Blood Pressure.. J Am Heart Assoc 13(7):e030142 PMID: 38497438
- 8. Valinsky WC et al.. 2019. Aldosterone and Ion Channels.. Vitam Horm 109:105-131 PMID: 30678852
